La imperiosa necesidad de reconstruir el sistema valorativo de los aportes científicos

Autores/as

  • Luis Carlos Silva Aycaguer Universidad de la Habana

DOI:

https://doi.org/10.17533/udea.rfnsp.e344778
|Resumen
= 306 veces | PDF
= 232 veces| | HTML
= 1 veces|

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Luis Carlos Silva Aycaguer, Universidad de la Habana

PhD en Ciencias Matemáticas y en Ciencias de la Salud.

Citas

Ioannidis JP. Why most published research findings are false. PLOS Medicine. 2005;2(8):0696-0701. DOI: https://doi.org/10.1371/journal.pmed.0020124

Begley CG, Ioannidis JP. Reproducibility in science: Improving the standard for basic and preclinical research. Circulation Research.2015;116(1):116-26. DOI: https://doi.org/10.1161/CIRCRESAHA.114.303819

Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533:452-4.

Silva LC. Crisis en la calidad de la ciencia médica: el papel del arbitraje en el nuevo desorden editorial. iris. Informação, Memória e Tecnologia.2018;4(1):8-21.

Gøtzsche P. Deadly medicines and organized crime. How big pharma has corrupted healthcare. New York: Radcliffe, 2013.

Budapest Open Access Initiative. Ten years on from the Budapest Open Access Initiative: Setting the default to open. Budapest Open Access Initiative; 2012. Disponible en: http://www.budapestopenaccessinitiative.org/boai-10-recommendations

Nosek BA, Bar-Anan Y. Scientific communication is changing and scientists should lead the way. Psychological Inquiry. 2012;23(3):308-14.

Bosman, J. Nine reasons why impact factors fail and using them may harm science. I&M / I&O 2.0; 2013. Disponible en: https://im2punt0.wordpress.com/2013/11/03/nine-reasons-why-impact-factors-fail-and-using-them-may-harm-science/

Parra S. Auge, caída y auge del remdesivir, el “esperanzador” antiviral para combatir el COVID-19; 2020. Disponible en: https://www.xataka.com/medicina-y-salud/auge-caida-auge-remdesivir-esperanzador-antiviral-para-combatir-covid-19

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of covid-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents; 2020:56(1): 105949. doi:https://doi.org/10.1016/j.ijantimicag.2020.105949

Baker P, Rogers K, et al. Trump’s aggressive advocacy of malaria drug for treating coronavirus divides medical community. The New York Times. 2020 abr. 6.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Retracted: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of covid-19: A multinational registry analysis. The Lancet, 2020(mayo 22):1-10. DOI: https://doi.org/10.1016/S0140-6736(20)31180-6

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim who solidarity trial results. 2020; oct. 15. Disponible en: https://bit.ly/3nYAPhC

Descargas

Publicado

2020-12-15

Cómo citar

1.
Silva Aycaguer LC. La imperiosa necesidad de reconstruir el sistema valorativo de los aportes científicos. Rev. Fac. Nac. Salud Pública [Internet]. 15 de diciembre de 2020 [citado 29 de noviembre de 2021];39(1):1-2. Disponible en: https://revistas.udea.edu.co/index.php/fnsp/article/view/344778

Número

Sección

Editorial